News Release

和其瑞医药出席BIOCHINA2025, 协力探索生物医药无界创新

为了天下的女儿们

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation

和其瑞医药单克隆抗体HMI-115获得CDE突破性疗法认定

致力于源头创新的和其瑞医药完成近2亿元人民币B+轮融资

Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia